Welcome to our dedicated page for FLXN news (Ticker: FLXN), a resource for investors and traders seeking the latest updates and insights on FLXN stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect FLXN's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of FLXN's position in the market.
Flexion Therapeutics (Nasdaq:FLXN) announced that Dr. Michael Clayman, President and CEO, will participate in an analyst-led fireside chat at the 42nd Annual Raymond James Institutional Investors Conference. The virtual event is set for 12:30 p.m. ET on March 1, 2021. Interested parties can access the live webcast through the Flexion Therapeutics website, which focuses on innovative local therapies for musculoskeletal conditions, particularly osteoarthritis. Key company values include focus, ingenuity, tenacity, transparency, and fun.
Flexion Therapeutics (Nasdaq:FLXN) announced the progression of its FX201 gene therapy into the high dose cohort of a Phase 1 trial after a positive review by an independent Data Monitoring Committee. The trial, targeting osteoarthritis treatment, will expand to include up to 20 additional patients in both low and mid dose cohorts. Initial data indicates FX201 is generally safe and well-tolerated, with early signs of clinical activity. Interim results are expected to be presented at a scientific meeting in 2021, with longer-term data anticipated by year-end.
Flexion Therapeutics announces a partnership with the National Basketball Retired Players Association (NBRPA) to increase awareness about osteoarthritis knee pain and promote ZILRETTA as a treatment option. The campaign features Sheryl Swoopes, WNBA legend and ZILRETTA patient, emphasizing her experiences with knee pain and treatment. The initiative aims to help former athletes and others suffering from OA, leveraging Swoopes' story to reach wider audiences. Flexion's CEO, Michael Clayman, expressed excitement about this collaboration, while NBRPA's Executive Director highlighted the importance of addressing knee pain among retired players.
Flexion Therapeutics (Nasdaq:FLXN) announces preliminary unaudited net sales of approximately $26.3 million for Q4 2020 and $85.5 million for the full year. The company reports a total of 4,248 accounts purchasing ZILRETTA, reflecting growth amid pandemic challenges. Adam Muzikant, Ph.D., is promoted to Chief Business Officer, enhancing leadership in commercial efforts. With approximately $175 million in cash and equivalents, Flexion aims to advance its pipeline for future growth. The upcoming earnings call will provide complete financial results.
Flexion Therapeutics (Nasdaq: FLXN) announced that CEO Michael Clayman, M.D., will participate in an analyst-led fireside chat during the Needham Virtual Epilepsy and Pain Specialty CNS Therapeutics Conference. This event is scheduled for December 11, 2020, at 2:15 p.m. ET. Investors can access the live webcast through the Flexion website. The company is dedicated to developing innovative local therapies for musculoskeletal conditions, including osteoarthritis, which is the most prevalent form of arthritis.
Flexion Therapeutics (Nasdaq:FLXN) has announced equity inducement grants to six new employees, totaling 22,798 restricted stock units. These grants, approved by the Compensation Committee and effective December 1, 2020, are designed to incentivize new hires in accordance with Nasdaq Listing Rule 5635(c)(4). The units will vest over four years, with 25% vesting each year, contingent on the employees' continued service. The grants are governed by the Company's 2013 Equity Incentive Plan.
Flexion Therapeutics (Nasdaq:FLXN) announced equity inducement grants to two new employees, totaling 3,315 restricted stock units, approved by the Board of Directors on November 2, 2020. These units will vest over four years, with 25% vesting annually, contingent upon the employees' continued service. This issuance aligns with Nasdaq Listing Rule 5635(c)(4) and is governed by the company's 2013 Equity Incentive Plan. Flexion specializes in developing treatments for musculoskeletal conditions, especially osteoarthritis.
Flexion Therapeutics (Nasdaq:FLXN) announced that CEO Michael Clayman will participate in a fireside chat at the 29th Annual Credit Suisse Virtual Healthcare Conference.
The event is set for November 11, 2020, starting at 8:45 a.m. ET. Investors can access the live webcast through Flexion's website. Flexion Therapeutics specializes in developing novel therapies for musculoskeletal conditions, especially osteoarthritis.
Flexion Therapeutics reported third-quarter 2020 financial results with net sales of $23.7 million for ZILRETTA, up from $21.8 million in 2019. The company recorded a net loss of $24.6 million, an improvement from a $38.2 million loss year-over-year. Cost of sales increased to $5.1 million, influenced by COVID-19 impacts. Flexion expects operating expenses between $172 million and $182 million for 2020. They advanced FX201 in clinical trials and aim for IND filing for FX301 in 2021.
Flexion Therapeutics (Nasdaq:FLXN) will release its third-quarter 2020 financial results on November 4, 2020, after U.S. market close. The company previously held a conference call on October 13, 2020, where preliminary net sales were discussed. A replay of the call is accessible via Flexion's corporate website. Flexion focuses on developing innovative local therapies for musculoskeletal conditions, particularly osteoarthritis. This announcement is pivotal for investors monitoring the company's performance in the biopharmaceutical sector.
